ロード中...
JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders
JAK inhibitors have been developed following the discovery of the JAK2V617F in 2005 as the driver mutation of the majority of non- BCR-ABL1 myeloproliferative neoplasms (MPNs). Subsequently, the search for JAK2 inhibitors continued with the discovery that the other driver mutations ( CALR and MPL) a...
保存先:
| 出版年: | F1000Res |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
F1000 Research Limited
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5773931/ https://ncbi.nlm.nih.gov/pubmed/29399328 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12688/f1000research.13167.1 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|